BIM
PCRX icon

BlackRock Investment Management’s Pacira BioSciences PCRX Stock Holding History

BlackRock Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$4.61M Sell
142,579
-7,224
-5% -$241K 0.01% 1638
2016
Q3 		$5.13M Buy
149,803
+14,348
+11% +$562K 0.01% 1464
2016
Q2 		$4.57M Buy
135,455
+9,206
+7% +$452K 0.01% 1497
2016
Q1 		$6.69M Buy
126,249
+3,612
+3% +$211K 0.01% 1182
2015
Q4 		$9.42M Buy
122,637
+135
+0.1% +$7.64K 0.01% 969
2015
Q3 		$5.04M Sell
122,502
-1,224
-1% -$75K 0.01% 1371
2015
Q2 		$8.75M Buy
123,726
+25,338
+26% +$2M 0.01% 1088
2015
Q1 		$8.74M Buy
98,388
+1,428
+1% +$145K 0.01% 1026
2014
Q4 		$8.6M Sell
96,960
-4,016
-4% -$380K 0.01% 1035
2014
Q3 		$9.79M Buy
100,976
+3,569
+4% +$347K 0.01% 924
2014
Q2 		$8.95M Buy
97,407
+21,347
+28% +$1.63M 0.01% 1038
2014
Q1 		$5.32M Buy
76,060
+327
+0.4% +$22.2K 0.01% 1322
2013
Q4 		$4.35M Sell
75,733
-1,969
-3% -$104K 0.01% 1443
2013
Q3 		$3.74M Buy
77,702
+4,937
+7% +$180K 0.01% 1481
2013
Q2 		$2.11M Buy
+72,765
New +$2.1M ﹤0.01% 1817

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BlackRock Investment Management's PCRX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Pacira BioSciences (PCRX) stake by 4.8% in Q4 2016, selling an estimated $241K and leaving 142,579 shares worth $4.61M. The position accounts for 0.01% of the portfolio, ranked #1638.

BlackRock Investment Management first reported a position in PCRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $9.79M in Q3 2014. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

  • BlackRock Investment Management held 142,579 shares of Pacira BioSciences worth $4.61M as of Q4 2016.
  • BlackRock Investment Management sold 7,224 Pacira BioSciences shares in Q4 2016, an estimated $241K.
  • Pacira BioSciences made up 0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #1638 holding.
  • BlackRock Investment Management first reported a position in Pacira BioSciences in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Pacira BioSciences position peaked at $9.79M in Q3 2014.
  • 182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.